Information Provided By:
Fly News Breaks for August 2, 2019
RARE
Aug 2, 2019 | 07:45 EDT
Wedbush analyst Laura Chico assumed coverage of Ultragenyx Pharmaceutical with an Otperform rating and $75 price target. In a research note to investors, Chico says while it is the early days for launches, with Crysvita continuing to grow, she thinks Ultragenyx is off to a good start so far. Chico says she sees the base business offering downside protection with fair value ~$59/share for Crysvita, Mepsevii and existing cash, while multiple readouts lie ahead for the DTX301 and DTX401 programs in the third quarter.
News For RARE From the Last 2 Days
RARE
RARE
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.